Lunchtime Leaders Market Snapshot – June 18, 2025

June 18, 2025

DENVER, Colo., Jun 18, 2025 (247marketnews.com)- As of midday trading, several stocks are making notable moves. Here’s a look at some of today’s most actively traded and newsworthy stocks:

Venu (NYSE:VENU) is in the spotlight after announcing the closure of a $10.25 million equity investment at a premium to the market. CEO, J.W. Roth revealed plans on the Schwab Network to build approximately $3 billion worth of venues over the next 3 to 4 years, including a $350 million amphitheater in McKinney, Texas. The company is utilizing a combination of public-private partnerships, fractional ownership sales, and sale-leaseback arrangements to fund these projects. Roth highlighted Venu’s financing model: “35 to 45% of our financing comes from municipality partnerships… another 35–45% from fractional ownership… the rest usually in the form of a sale leaseback.”

Venu also filed an 8-K confirming the close of a $10.25 million equity investment with an institutional investor at a premium, with convertible preferred shares priced effectively at $15 per share.

VENU is nearing its all-time high of $13.132 and is looking like it could take off, as its borrow fee approaching 39% places it officially in “Hard to Borrow” territory, as it’s looking like it’s about to take a blue-sky ride, with shorts already paying a steep price just to stay in the game.

Like Venu, Aptevo Therapeutics (NASDAQ:APVO) was on our morning watch-list, but it’s already pulled way back from today’s high of $13.1099, after garnering attention following the release of promising data from its Phase 1b/2 RAINIER trial. The trial evaluates mipletamig, a bispecific antibody targeting CD123 and CD3, in combination with standard-of-care venetoclax and azacitidine for newly diagnosed, unfit acute myeloid leukemia (AML) patients. Notably, 85% of evaluable patients achieved remission, with no dose-limiting toxicities observed. The third dosing cohort is nearing full enrollment.

Citi raised NVIDIA’s (NASDAQ:NVDA) price target to $180 from $150, maintaining a Buy rating after strong Q1 2025 results ($44.06 billion revenue, 96 cents EPS, beating estimates). A June 18 report projects NVDA hitting $200 in 2025, driven by 92% GPU market share and a Saudi deal for 18,000 GB300 Blackwell chips.

Tesla (NASDAQ:TSLA) gained momentum after President Trump delayed 50% EU tariffs on May 29, easing trade fears. Elon Musk’s increased focus on Tesla, announced May 28, and a strong Q1 2025 (revenue up 10% year-over-year) bolster sentiment.

Marvell Technology (NASDAQ:MRVL) hosted a custom AI silicon event on June 17, showcasing advancements in AI chip technology. The company guided for $1.88 billion in Q1 2026 revenue and $0.61 EPS, a significant improvement from $1.16 billion and $0.24 EPS last year.

Circle (NYSE:CIRC) the issuer of USDC stablecoin, filed for a confidential IPO in January 2025, with speculation of a Q3 2025 listing. On June 12, Circle announced a partnership with Binance to expand USDC adoption, boosting crypto market sentiment.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, APVO, NVDA, TSLA, MRVL, CIRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.